Found 6 Ovarian Cancer trials
A listing of Ovarian Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Combination ATR and PARP Inhibitor (CAPRI) trial with AZD6738 and Olaparib in recurrent ovarian cancer
Phase 2
This project studies combination AZD6738 and olaparib (Lymparza) to treat recurrent ovarian cancer. It will examine 1) the safety and tolerability of this drug combination and 2) the overall response rate (tumor strinkage rate) of this therapy. All study patients have recurrent ovarian cancer. None of the patients have standard …
A study of ceralasertib (AZD6738) as monotherapy and in combination with other anticancer agents in patients with advanced solid malignancies Module 5 (ceralasertib in combination with AZD5305) (ANGEL)
Penn Gynecologic Oncology is participating in Module 5 for ovarian cancer patients.
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NRG-GY031)
Phase 1
To determine the maximum tolerated dose (MTD) and the dose-limiting toxicities (DLTs) for combination of ATR inhibitor (M1774) and BET inhibitor (ZEN003694) in women with recurrent clear cell, endometrioid, and platinum resistant high grade serous ovarian carcinoma (HGSOC) and clear cell and endometrioid endometrial carcinoma irrespective of ARID1A status.The target …
A Study to Compare Two Surgical Procedures in Individuals with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk- NRG-CC008)
The purpose of this study is to determine if two surgical procedures, the usual approach of removing the fallopian tubes and ovaries and the other approach of removing the fallopian tubes at this time with the plan to remove the ovaries at a later time, are no different for ovarian …
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies (Xencor)
Phase 2
The purpose of the study is to assess whether an investigational drug, called XmAb20717, has any effects on certain types of cancers and if it is safe and well tolerated.
GEN1047 for Solid Tumors (GENMAB)
Phase 1/2
The overall objective of the study is to determine the maximum tolerated dose/maximum administered dose and to characterize the safety profile of GEN1047. The primary outcome variables are, dose limiting toxicities, adverse events and safety laboratory parameters as well as objective response rate based on RECIST v1.1. The secondary outcome …
